Business Overview
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies based on its proprietary RPx platform, an engineered HSV-1 backbone designed to selectively replicate in tumors and activate anti-tumor immune responses. The company's lead product candidate RP1 (vusolimogene oderparepvec) is in late-stage development for advanced melanoma in combination with nivolumab, with a resubmitted BLA under FDA review targeting approval in 2026, while RP2 and RP3 are being advanced for additional tumor types including uveal melanoma, hepatocellular carcinoma, and other solid tumors.
Forward Guidance
The company states it "expects" the Phase 2/3 transition for the REVEAL study (RP2 in metastatic uveal melanoma) "in the first quarter of 2027." It plans to "release preliminary HCC data by the end of 2026" from the RP2 hepatocellular carcinoma trial. The company announced on May 29, 2026 that "the FDA indicated that it will treat the BLA resubmission as an urgent matter upon receipt and will prioritize its review." On June 26, 2026, the FDA accepted the BLA resubmission "as a Class 1 resubmission with an action date of August 2, 2026" and stated "they would convene an advisory committee meeting in late July 2026."
Key Risk Factors
Key risks include: (1) the uncertainty of FDA approval for RP1, as the company received a second Complete Response Letter in April 2026 and faces potential restructuring if accelerated approval is not achieved; (2) clinical trial execution and timing risks, including patient enrollment, trial design acceptance by the FDA, and the ability to generate clinical data that satisfies regulatory requirements; (3) manufacturing risks related to the company's in-house manufacturing operations, including obtaining sufficient raw materials and maintaining FDA approval; (4) competitive and market risks, including the rate of market acceptance of oncolytic immunotherapy as an emerging drug class and competition from established cancer treatment modalities; and (5) intellectual property risks regarding the scope and maintenance of patent protection for the RPx platform and potential infringement claims.
